Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01782222 · ClinicalTrials.gov registry record · Phase 4
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
A Phase 4 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
NCT01782222 is a Phase 4 study that has completed, run by UCB Biosciences. The registered enrollment target is 122 participants.
The verdict
NCT01782222, a Phase 4 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
Study Summary
This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.
Interventions
- OTHER Placebo
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01782222
The ClinicalTrials.gov registry entry for NCT01782222 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01782222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01782222 about?
NCT01782222 is a clinical study titled "Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy". This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.
What is the current status of trial NCT01782222?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2013-02. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01782222?
The interventions under investigation include: Placebo (OTHER), Rotigotine (DRUG).
Who is sponsoring clinical trial NCT01782222?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.